A Phase 4 interventional study of CYP2C19 based dosing Proton Pump Inhibitors and Conventional proton pump inhibitor dose in Gastroesophageal Reflux Disease With Esophagitis, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Florida · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Esophagitis, Peptic with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Esophagitis, Peptic · United States.
Among the 15 studies in Esophagitis, Peptic with a site in United States, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 4, and was the 15th registered.
83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.
Browse Esophagitis, Peptic studies →2 of the 15 studies in Esophagitis, Peptic with a site in United States are open now. Recruiting first, the newest first:
University of California, Irvine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 135 across 60 interventional studies indexed under Esophagitis, Peptic.
Median enrollment 180 across the 14 interventional studies, 65 across the 1 observational. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,288 studies on the registry; 200 are open to participants now.
Of its 180 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 1 study filed under Esophagitis, Peptic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Esophagitis, Peptic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
proton pump inhibitor dose based on CYP2C19 phenotypes
Drug: CYP2C19 based dosing Proton Pump Inhibitors
conventional proton pump inhibitor dose of Pantoprazole 40 mg once or twice daily
Drug: Conventional proton pump inhibitor dose
Pantoprazole dosing based on CYP2C19 phenotypes
conventional PPI dose of Pantoprazole 40 mg once or twice daily
Improvement of Los Angeles (LA) classification of Erosive Esphagitis (EE) grade
Assessment of erosive esophagitis grade to determine healing in both arms. Healing would be measured by endoscopic regression of errosive esophagitis (EE) to a lower degree of inflammation. Previously assigned baseline numerical values per the LA classification of EE will be used to calculate the degree of healing in each arm at the 8th week follow up, e.g. LA grade D (initial EGD) to LA grade A (repeat EGD) would yield a score of 3 (LA D \[5\] - LA A \[2\]). A higher score hence indicating superior healing of EE.
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Dec 2027, 13 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.